{"source_content":"医药行业研究p1东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研DONGXINGSECURITIESwww.dxzq.net.cn2021年1月21日血制品行业：白蛋白进入提价窗口期—2020年血制品批签发跟踪东兴医药团队：胡博新电话010-66554032执业证书编号：S1480519050003王敏杰电话010-66554041执业证书编号：S1480119070047医药行业研究p2东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研投资要点➢2020年血液制品批签发回顾：疫情推动静丙增长，白蛋白国产进口两重天•白蛋白：2020年全年白蛋白批签发总量5938万支（+9.8%），其中国产批签发2102万支（-2.82%），进口批签发3835万支（+18.2%）。2020年Q3-Q4疫情影响传导至供给端，下半年国产白蛋白产品批签发量增速下降明显•静丙：2020年全年，静注人免疫球蛋白批签发1321万支，同比增长7.17%。2020年Q1受疫情需求推动，静丙批签发大幅增长（+100.57%），2020Q2-Q4，需求端国内疫情控制致增量需求回落，正常诊疗亦处于恢复之中，供给端采浆量下滑传导至产成品，静丙Q2-Q4批签发有所放缓➢2021年血液制品展望：短期看白蛋白进入提价窗口期，长期看资源属性+需求稳步提升•海外疫情3月爆发并持续，3-10月美国采浆站滚动访问人次下滑50%，国际血制品巨头之一Grifols预计2020年财年采浆量-15%，参考8-9个月的生产和进口检疫周期，预计从2021年初开始影响白蛋白进口。•2021年国内诊疗秩序恢复，国内市场2021年白蛋白需求量较2020年恢复性增长•进口白蛋白占国内市场的比例超过60%，而且份额集中，如果进口下降，白蛋白可能供给紧张，价格有望上行，国内血液制品有望实现量价齐升➢投资建议：预计2021年初进入白蛋白提价的窗口期，国产白蛋白迎来量价提升阶段，建议从市场份额与产能提升潜力进行筛选，其中龙头企业更具备定价权，提价更占据主动，在进口供应短缺阶段，更具备产能供给弹性的企业有望抢占更多市场的份额，关注行业龙头和浆量提升高弹性企业，天坛生物、华兰生物、博雅生物、双林生物➢风险提示：浆站采浆量不及预期，产品销售不达预期，新品研发进展不及预期，产品潜在安全性风险医药行业研究p3东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研目录❑1.2020批签发概况：疫情影响国内采浆，下半年大品种批签发放缓❑2.2020年分品种批签发情况⚫人血白蛋白⚫静注人免疫球蛋白⚫人凝血酶原复合物⚫人纤维蛋白原⚫人凝血因子VIII⚫狂犬病人免疫球蛋白⚫破伤风人免疫球蛋白⚫乙型肝炎人免疫球蛋白❑3.2021年：短期出厂价有望提升，资源属性+需求提升稳定长期增长❑4.投资建议：关注行业龙头和浆量提升高弹性企业❑5.风险提示医药行业研究p4东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研➢人血白蛋白：折合10g规格，进口+国产（5938万支，同比+9.8%），国产（2102万支，同比-2.82%），华兰（245万支，同比-16.9%），博雅（90万支，同比+4.5%），天坛（433万支，同比+0.3%）➢静注人免疫球蛋白：折合2.5g规格，整体（1321万支，同比+7.2%），华兰（138万支，同比-24.3%），博雅（65万支，同比+12.1%），天坛（312万支，同比+6.4%）2020年：疫情影响，静丙与国产人白前增后降201920202019Q12020Q12019Q22020Q22019Q32020Q32019Q42020Q4进口总计3244.393835.3118.21%407.241011.85148.46%898.471019.5513.48%948.28819.75-13.55%990.39984.17-0.63%进口占比60.00%64.59%/46.07%65.66%/63.73%65.81%/59.75%56.88%/64.87%69.99%/国产总计2163.182102.23-2.82%476.69529.2911.03%511.38529.573.56%638.76621.38-2.72%536.35421.99-21.32%国产占比40.00%35.41%/53.93%34.34%/36.27%34.19%/40.25%43.12%/35.13%30.01%/总计5407.575937.549.80%883.931541.1374.35%1409.851549.129.88%1587.031441.13-9.19%1526.751406.16-7.90%静丙（折算规格/2.5g)总计1232.341320.677.17%229.32459.94100.57%258.42266.353.07%449.49310.77-30.86%295.11283.61-3.90%狂犬病人免疫球蛋白（折算规格/200IU)总计1270.461169.83-7.92%203.66247.0721.31%293.33338.7915.50%447.62263.26-41.19%325.85320.71-1.58%破伤风人免疫球蛋白（折算规格/250IU)总计659.07618.44-6.16%114.21162.0841.92%147.86138.72-6.18%233.06127.29-45.38%163.94190.3416.10%乙型肝炎人免疫球蛋白（折算规格/100IU)总计224.92216.32-3.83%13.2150.07279.02%94.8827.29-71.24%18.1668.27276.03%98.6870.69-28.37%静注乙型肝炎人免疫球蛋白（折算规格/2000IU)总计5.656.118.23%0.390.7384.04%1.784.72165.07%2.740.67-75.66%0.730.00-100.00%纤维蛋白原（折算规格/0.5g)总计84.10139.8866.32%26.9526.69-0.97%15.4336.94139.36%22.4919.28-14.29%19.2256.97196.37%凝血酶原（折算规格/200IU)总计95.01151.5759.54%9.9936.01260.26%24.9648.3193.55%37.7631.82-15.73%22.3035.4458.93%凝血因子Ⅷ（折算规格/200IU)总计173.43198.4314.41%33.6360.1678.89%32.5843.7134.17%52.9964.8422.36%54.2429.72-45.20%同比增长折算后批签发折算后批签发折算后批签发血制品名称国产/进口折算后批签发折算后批签发同比增长同比增长人血白蛋白（折算规格/10g)免疫球蛋白凝血因子类同比增长同比增长资料来源：wind，公司公告，东兴证券研究所医药行业研究p5东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研➢人纤维蛋白原：折合0.5g规格，整体（139.9万支，同比+66.3%），博雅（26.3万支，同比-3.6%）➢人凝血酶原复合物：折合200IU规格，整体（151.6万支，同比+59.5%），华兰（55.3万支，同比+28.5%）➢人凝血因子VIII：折合200IU规格，整体（198.4万支，同比+14.4%），华兰（48.2万支，同比-23.4%）➢狂犬病人免疫球蛋白：折合200IU规格，整体（1169.8万支，同比-7.9%），华兰（99.2万支，同比-21.2%）➢破伤风人免疫球蛋白：折合250IU规格，整体（618.4万支，同比-6.2%），华兰（165.6万支，同比-0.2%）➢乙型肝炎人免疫球蛋白：折合100IU规格，整体（216.3万支，同比-3.8%），华兰（47.7万支，同比+86.2%）2020年：因子类大幅增长，特免小幅下滑201920202019Q12020Q12019Q22020Q22019Q32020Q32019Q42020Q4进口总计3244.393835.3118.21%407.241011.85148.46%898.471019.5513.48%948.28819.75-13.55%990.39984.17-0.63%进口占比60.00%64.59%/46.07%65.66%/63.73%65.81%/59.75%56.88%/64.87%69.99%/国产总计2163.182102.23-2.82%476.69529.2911.03%511.38529.573.56%638.76621.38-2.72%536.35421.99-21.32%国产占比40.00%35.41%/53.93%34.34%/36.27%34.19%/40.25%43.12%/35.13%30.01%/总计5407.575937.549.80%883.931541.1374.35%1409.851549.129.88%1587.031441.13-9.19%1526.751406.16-7.90%静丙（折算规格/2.5g)总计1232.341320.677.17%229.32459.94100.57%258.42266.353.07%449.49310.77-30.86%295.11283.61-3.90%狂犬病人免疫球蛋白（折算规格/200IU)总计1270.461169.83-7.92%203.66247.0721.31%293.33338.7915.50%447.62263.26-41.19%325.85320.71-1.58%破伤风人免疫球蛋白（折算规格/250IU)总计659.07618.44-6.16%114.21162.0841.92%147.86138.72-6.18%233.06127.29-45.38%163.94190.3416.10%乙型肝炎人免疫球蛋白（折算规格/100IU)总计224.92216.32-3.83%13.2150.07279.02%94.8827.29-71.24%18.1668.27276.03%98.6870.69-28.37%静注乙型肝炎人免疫球蛋白（折算规格/2000IU)总计5.656.118.23%0.390.7384.04%1.784.72165.07%2.740.67-75.66%0.730.00-100.00%纤维蛋白原（折算规格/0.5g)总计84.10139.8866.32%26.9526.69-0.97%15.4336.94139.36%22.4919.28-14.29%19.2256.97196.37%凝血酶原（折算规格/200IU)总计95.01151.5759.54%9.9936.01260.26%24.9648.3193.55%37.7631.82-15.73%22.3035.4458.93%凝血因子Ⅷ（折算规格/200IU)总计173.43198.4314.41%33.6360.1678.89%32.5843.7134.17%52.9964.8422.36%54.2429.72-45.20%同比增长折算后批签发折算后批签发折算后批签发血制品名称国产/进口折算后批签发折算后批签发同比增长同比增长人血白蛋白（折算规格/10g)免疫球蛋白凝血因子类同比增长同比增长资料来源：wind，公司公告，东兴证券研究所医药行业研究p6东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研目录❑1.2020批签发：疫情影响国内采浆，下半年大品种批签发放缓❑2.2020年分品种批签发情况⚫人血白蛋白⚫静注人免疫球蛋白⚫人凝血酶原复合物⚫人纤维蛋白原⚫人凝血因子VIII⚫狂犬病人免疫球蛋白⚫破伤风人免疫球蛋白⚫乙型肝炎人免疫球蛋白❑3.2021年：短期出厂价有望提升，资源属性+需求提升稳定长期增长❑4.投资建议：关注行业龙头和浆量提升高弹性企业❑5.风险提示医药行业研究p7东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研进口+国产（折合10g，按季度）进口+国产（折合10g，按年）0%10%20%30%40%50%05010020132014201520162017201820192020批签发量（折合10g，百万支）-50%0%50%100%01020Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q320132014201520162017201820192020批签发量（折合10g，百万支）国产（折合10g，按年）国产（折合10g，按季度）-50%0%50%100%0.010.020.030.020132014201520162017201820192020批签发量（折合10g，百万支）-40%-20%0%20%40%02468Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q320132014201520162017201820192020批签发量（折合10g，百万支）2.1白蛋白—全年批签发+9.4%，下半年批签发放缓➢2014-2020年，白蛋白批签发总量平稳增长，年均复合增速约为+12.89%➢2020年全年批签发总量5938万支（+9.8%），其中国产批签发2102万支（-2.82%），进口批签发3835万支（+18.2%）。➢国产：受国内疫情影响，2020年Q1国内血制品企业采浆量下滑，上半年全行业采浆量下滑约20%。由采浆到产品批签发完成滞后时间约6-9个月，2020年Q3-Q4疫情影响传导至供给端，下半年白蛋白产品国内批签发量增速下降明显。2020年Q1/Q2/Q3/Q4国产白蛋白批签发量分别为529万支/530万支/621万支/422万支，同比增速分别为+11.0%/+3.6%/-2.7%/-21.3%。➢进口：2020年上半年，进口白蛋白产品集中获批，增速较快，2020年下半年进口产品批签发增速亦有所放缓，2020Q1/Q2/Q3/Q4进口白蛋白批签发量分别为1012万支/1020万支/820万支/984万支,同比增速分别为+148.5%/+13.5%/-13.6%/-0.6%进口（折合10g，按年）进口（折合10g，按季度）0%50%100%0.020.040.060.020132014201520162017201820192020批签发量（折合10g，百万支）-100%0%100%200%051015Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q320132014201520162017201820192020批签发量（折合10g，百万支）资料来源：wind，公司公告，东兴证券研究所医药行业研究p8东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研2.1白蛋白—2020年进口持续扩大➢2014-2019年国产白蛋白和进口白蛋白批签发比例相对稳定，其中国产白蛋白批签发占比约40%-43%，进口白蛋白批签发占比约57%-60%➢2020年，国产白蛋白批签发增长慢于进口白蛋白批签发增长，国产白蛋白批签发占比有所下滑，2020年Q1/Q2/Q3/Q4国产批签发占比分别为34%/34%/43%/30%，进口白蛋白批签发占比分别为66%/66%/57%/70%➢2020年全年，国产白蛋白批签发占比降至35.4%，进口白蛋白批签发占比增至64.6%，国产白蛋白批签发比例降至近5年最低位进口+国产份额（折合10g，按年）58.5%57.6%57.1%57.5%59.6%60.0%64.6%41.5%42.4%42.9%42.5%40.4%40.0%35.4%0%20%40%60%80%100%2014201520162017201820192020进口国产进口+国产份额（折合10g，按季度）36%40%44%41%54%36%40%35%34%34%43%30%64%60%56%59%46%64%60%65%66%66%57%70%0%10%20%30%40%50%60%70%80%90%100%Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4进口百分比国产百分比201820192020资料来源：wind，公司公告，东兴证券研究所医药行业研究p9东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研华兰生物（折合10g，按年）博雅生物（折合10g，按年）天坛生物（折合10g，按年）-50%0%50%100%0.02.04.020132014201520162017201820192020批签发量（折合10g，百万支）-50%0%50%100%0.00.51.01.520132014201520162017201820192020批签发量（折合10g，百万支）-50%0%50%100%0.02.04.06.020132014201520162017201820192020批签发量（折合10g，百万支）2.1国产白蛋白➢2020年全年，批签发份额前5位企业分别为天坛生物、上海莱士、泰邦生物、华兰生物、远大蜀阳➢其中天坛生物批签发433万支，同比+0.3%，批签发份额20.61%，份额+0.64pct；华兰生物批签发245万支，同比-16.9%，批签发份额11.67%，份额-1.97pct；博雅生物批签发90万支，同比+4.5%，批签发份额4.27%，份额+0.3pct；双林生物批签发118万支，同比-3.4%，批签发份额5.62%，份额-0.03pct国产份额（折合10g，2020）双林生物（折合10g，按年）国产份额（折合10g，按年）天坛生物,20.61%泰邦生物,14.88%上海莱士,15.00%华兰生物,11.67%远大蜀阳药业,8.52%康宝生物,2.35%博雅生物,5.62%双林生物,4.27%卫光生物,5.34%南岳生物,2.84%其它六家,8.89%-50%0%50%100%0.00.51.01.520132014201520162017201820192020批签发量（折合10g，百万支）0%100%2014201520162017201820192020天坛生物泰邦生物上海莱士华兰生物远大蜀阳药业康宝生物双林生物博雅生物资料来源：wind，公司公告，东兴证券研究所医药行业研究p10东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研Octapharma（折合10g，按季度）Baxter（折合10g，按季度）CSL（折合10g，按季度）2.1进口白蛋白进口份额（折合10g，2020）Grifols（折合10g，按季度）进口份额（折合10g，按年）0%100%2014201520162017201820192020CSLBehringGrifolsBaxterOctapharma绿十字（韩国）SKBiotestCSLBehring,33.60%Grifols,20.94%Baxter,19.53%Octapharma,24.31%绿十字（韩国）,1.10%Biotest,0.52%-100%-50%0%50%100%0246Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q320132014201520162017201820192020批签发量（折合10g，百万支）-200%-100%0%100%200%024Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q320132014201520162017201820192020批签发量（折合10g，百万支）-200%0%200%400%600%0123Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q320132014201520162017201820192020批签发量（折合10g，百万支）-200%0%200%400%600%024Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q320132014201520162017201820192020批签发量（折合10g，百万支）➢2020年全年，CSL、Octapharma、Baxter、Grifols四大血制品企业批签发量占进口批签发98.38%➢其中，CSL批签发1289万支，同比-11.66%，批签发份额33.60%，份额-11.36pct；其中Q1/Q2/Q3/Q4批签发量分别为279万支/445万支/271万支/294万支，同比增速分别为+23.3%/+52.9%/-44.1%/-35.6%➢Octapharma批签发933万支，同比+121.2%，批签发份额24.31%，份额+11.32pct；其中Q1/Q2/Q3/Q4批签发量分别为187万支/232万支/147万支/367万支，Q2/Q3/Q4同比增速分别为+100.9%/+11.0%/+111.1%➢Baxter批签发749万支，同比+6.51%，批签发份额19.53%，份额-2.15pct；其中Q1/Q2/Q3/Q4批签发量分别为258万支/237万支/142万支/113万支，同比增速分别为+108.2%/-28.5%/+19.8%/-13.3%➢Grifols批签发803万支，同比+29.02%，批签发份额20.94%，份额+1.75pct；其中Q1/Q2/Q3/Q4批签发量分别为257万支/97万支/250万支/199万支，同比增速分别为+420.2%/-36.1%/+23.9%/-9.2%资料来源：wind，公司公告，东兴证券研究所医药行业研究p11东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研国产（折合2.5g，按年）国产（折合2.5g，按季度）国产份额（折合2.5g，2020）0%10%20%30%40%50%0510152014201520162017201820192020批签发量（折合2.5g，百万支）-50%0%50%100%150%0.02.04.06.0Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q320132014201520162017201820192020批签发量（折合2.5g，百万支）天坛生物,23.63%泰邦生物,12.97%上海莱士,17.28%华兰生物,10.44%远大蜀阳药业,7.22%康宝生物,3.13%卫光生物,5.41%博雅生物,4.91%双林生物,5.21%其它5家,9.80%2.2静丙—Q1大幅增长，Q2-Q4增速回落，全年+7.2%➢2014-2020年，静注人免疫球蛋白（含冻干静注人免疫球蛋白，下同）批签发量年均复合增长约+10.96%➢2020年全年，静注人免疫球蛋白折算后批签发1321万支，同比增长7.17%➢2020年Q1受疫情需求推动，静丙批签发大幅增长（+100.57%），2020Q2-Q4，需求端国内疫情控制致增量需求回落，正常诊疗亦处于恢复之中，供给端采浆量下滑传导至产成品，静丙Q2-Q4批签发有所放缓，Q2/Q3/Q4同比增速分别为+3.07%/-30.86%/-3.90%➢2020年，批签发份额排名前五位企业分别为天坛生物（23.6%）、上海莱士（17.3%）、泰邦生物（13.0%）、华兰生物（10.4%）、远大蜀阳（7.2%）国产份额（折合2.5g，按年）0%50%100%2014201520162017201820192020天坛生物泰邦生物上海莱士华兰生物远大蜀阳药业康宝生物卫光生物博雅生物双林生物资料来源：wind，公司公告，东兴证券研究所医药行业研究p12东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研华兰生物（折合2.5g，按年）博雅生物（折合2.5g，按年）天坛生物（折合2.5g，按年）-50%0%50%100%0.01.02.02014201520162017201820192020批签发量（折合2.5g，百万支）-50%0%50%100%0.00.51.02014201520162017201820192020批签发量（折合2.5g，百万支）-20%0%20%40%0.02.04.02014201520162017201820192020批签发量（折合2.5g，百万支）➢2020年全年，天坛生物批签发312万支，同比+6.38%，批签发份额23.6%，份额-0.2pct；➢华兰生物批签发138万支，同比-24.33%，批签发份额10.4%，份额-4.3pct；➢双林生物批签发69万支，同比+29.01%，批签发份额5.2%，份额+0.9pct；➢博雅生物批签发65万支，同比+12.12%，批签发份额4.9%，份额+0.2pct；2.2静丙—Q1大幅增长，Q2-Q4增速回落，全年+7.2%-50%0%50%100%0.00.51.02014201520162017201820192020批签发量（折合2.5g，百万支）双林生物（折合2.5g，按年）资料来源：wind，公司公告，东兴证券研究所医药行业研究p13东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研国产（折合200IU，按年）国产（折合200IU，按季度）华兰生物（折合200IU，按年）-50%0%50%100%0.0100.0200.02014201520162017201820192020批签发量（折合200IU，万支）-200%0%200%400%600%800%0.020.040.060.0Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q320132014201520162017201820192020批签发量（折合200IU，万支）-50%0%50%100%0.050.0100.02014201520162017201820192020批签发量（折合200IU，万支）2.3因子类产品同比大幅增长--人凝血酶原复合物➢人凝血酶原复合物、人凝血因子VIII、人纤维蛋白原等因子类产品近年整体增速相对较快，2020年同比亦实现大幅增长➢其中人凝血酶原复合物2014-2020年批签发量年均复合增速约为+17.23%➢2020年全年，人凝血酶原复合物整体批签发151.6万支，同比+59.54%，其中Q1/Q2/Q3/Q4批签发量分别为36.0万支/48.3万支/31.8万支/35.4万支，同比增速分别为+260.26%/+93.55%/-15.73%/+58.93%➢2020年泰邦生物、华兰生物、南岳生物3家企业获得凝血酶原复合物批签发，其中泰邦生物批签发居主导地位（58.4%份额）➢其中华兰生物批签发55.3万支，同比+28.5%，批签发份额36.5%，份额-8.81pct0%50%100%2014201520162017201820192020华兰生物南岳生物上海新兴医药泰邦生物天坛生物国产份额（折合200IU，按年）资料来源：wind，公司公告，东兴证券研究所医药行业研究p14东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研国产（折合0.5g，按年）国产（折合0.5g，按季度）国产份额（折合0.5g，2020）-50%0%50%100%0.050.0100.0150.020132014201520162017201820192020批签发量（0.5g，万支）-100%0%100%200%300%400%0.020.040.060.0Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q320132014201520162017201820192020批签发量（0.5g，万支）同比增速2.4因子类产品同比大幅增长--人纤维蛋白原博雅生物（折合0.5g，按年）-100%0%100%200%0.020.040.060.02014201520162017201820192020批签发量（0.5g，万支）➢2014-2016年，人纤维蛋白原批签发量由35.5万支增长至96.3万支，2016-2019年，批签发量整体平稳，2016-2019年均复合增速约为-4.42%➢2020年全年，人纤维蛋白原整体批签发139.9万支（+66.32%），2020年Q1/Q2/Q3/Q4分别批签发26.7/36.9/19.3/57.0万支，分别同比增长-0.97%/+139.36%/-14.29%/+196.37%➢2020年，上海莱士、派斯菲科、博雅生物、泰邦生物、绿十字（中国）、卫光生物等6家企业获得批签发。➢其中博雅生物批签发26.3万支，同比-3.58%，批签发份额18.8%，份额-13.66pct；派斯菲科批签发31.6万支，同比+720.35%，批签发份额22.6%，份额+17.99pct；博雅生物,18.84%上海莱士,35.69%泰邦生物,17.27%卫光生物,1.52%绿十字（中国）,4.13%派斯菲科,22.56%派斯菲科（折合0.5g，按年）-500%0%500%1000%0.020.040.02014201520162017201820192020批签发量（0.5g，万支）资料来源：wind，公司公告，东兴证券研究所医药行业研究p15东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研国产（折合200IU，按年）国产（折合200IU，按季度）华兰生物（折合200IU，按年）-50%0%50%100%0.0100.0200.0300.02014201520162017201820192020批签发量（折合200IU，万支）-100%0%100%200%300%0.020.040.060.080.0Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q320132014201520162017201820192020批签发量（折合200IU，万支）-50%0%50%100%0.050.0100.02014201520162017201820192020批签发量（折合200IU，万支）2.5因子类产品同比大幅增长--人凝血因子VIII➢2014-2020年，人凝血因子VIII年均复合增速+15.55%➢2020年人凝血因子VIII整体批签发198.4万支，同比+14.41%，其中Q1/Q2/Q3/Q4批签发量分别为60.2万支/43.7万支/64.8万支/29.7万支，同比增速分别为+78.89%/+34.17%/+22.36%/-45.2%➢2020年，上海莱士、华兰生物、泰邦生物、绿十字（中国）、天坛生物等5家企业获得批签发➢其中华兰生物批签发48.2万支，同比-23.38%，批签发份额24.3%，份额-11.97pct；天坛生物新增人凝血因子VIII批签发，批签发量0.4万支，批签发份额0.19%；0.00.10.20.30.42014201520162017201820192020批签发量（折合200IU，万支）天坛生物（折合200IU，按年）0%50%100%2014201520162017201820192020华兰生物绿十字（中国）上海莱士上海新兴医药泰邦生物天坛生物国产份额（折合200IU，按季度）资料来源：wind，公司公告，东兴证券研究所医药行业研究p16东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研-200%0%200%400%0.0100.0200.02014201520162017201820192020批签发量（折合200IU，万支）国产（折合200IU，按年）国产（折合200IU，按季度）国产份额（折合200IU，2020）2.6特免产品同比小幅下滑--狂犬病人免疫球蛋白➢2016-2019年，狂犬病人免疫球蛋白批签发量大幅增长，由2016年309.9万支增长至2019年1270.5万支，年均复合增速达+60.05%➢2020年全年，狂犬病人免疫球蛋白批签发1169.8万支，同比-7.92%，其中Q1/Q2/Q3/Q4批签发量分别为247.1万支/338.8万支/263.3万支/320.7万支，同比增速分别为+21.31%/+15.50%/-41.19%/-1.58%➢2020年，共10家企业获得批签发，批签发量排名前5的企业为卫光生物、远大蜀阳、泰邦生物、上海莱士、双林生物➢双林生物批签发134.1万支，同比-12.84%，批签发份额11.5%，份额-0.65pct；华兰生物批签发99.2万支，同比-21.18%，批签发份额8.5%，份额-1.43pct；博雅生物批签发80.6万支，同比+22.93%，批签发份额6.9%，份额+1.73pct-100%0%100%0.0500.01000.01500.020132014201520162017201820192020批签发量（折合200IU，万支）-100%0%100%200%0.0100.0200.0300.0400.0500.0Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q320132014201520162017201820192020批签发量（折合200IU，万支）远大蜀阳药业,17.33%双林生物,11.47%泰邦生物,14.45%上海莱士,11.58%卫光生物,17.39%华兰生物,8.48%天坛生物,5.71%博雅生物,6.89%其他两家,6.71%双林生物（折合200IU，按年）华兰生物（折合200IU，按年）博雅生物（折合200IU，按年）-200%0%200%400%0.0100.0200.02014201520162017201820192020批签发量（折合200IU，万支）-100%0%100%200%300%0.050.0100.02014201520162017201820192020批签发量（折合200IU，万支）资料来源：wind，公司公告，东兴证券研究所医药行业研究p17东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研国产（折合250IU，按年）国产（折合250IU，按季度）国产份额（折合250IU，2020）2.7特免产品同比小幅下滑--破伤风人免疫球蛋白-50%0%50%100%0.0500.01000.020132014201520162017201820192020批签发量（折合250IU，万支）-100%-50%0%50%100%150%200%0.050.0100.0150.0200.0250.0Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q320132014201520162017201820192020批签发量（折合250IU，万支）➢2014-2019年，破伤风人免疫球蛋白批签发量整体增长迅速，由2014年209.6万支增长至2019年659.1万支，年均复合增速达+25.75%➢2020年全年，破伤风人免疫球蛋白批签发618.4万支，同比-6.16%，其中Q1/Q2/Q3/Q4批签发量分别为162.1万支/138.7万支/127.3万支/190.3万支，同比增速分别为+41.92%/-6.18%/-45.38%/+16.1%➢2020年，共8家企业获得批签发，批签发量排名前5的企业为华兰生物、泰邦生物、天坛生物、远大蜀阳、双林生物➢华兰生物批签发165.6万支，同比-0.22%，批签发份额26.8%，份额1.60pct；天坛生物批签发96.2万支，同比-30.72%，批签发份额15.6%，份额-5.51pct；双林生物批签发72.5万支，同比36.98%，批签发份额11.7%，份额3.69pct泰邦生物,22.05%华兰生物,26.78%天坛生物,15.56%远大蜀阳药业,14.23%上海莱士,7.50%双林生物,11.73%卫光生物,1.84%河北大安制药,0.32%华兰生物（折合250IU，按年）天坛生物（折合250IU，按年）双林生物（折合250IU，按年）-100%0%100%200%300%0.0100.0200.02014201520162017201820192020批签发量（折合250IU，万支）-50%0%50%100%0.050.0100.0150.02014201520162017201820192020批签发量（折合250IU，万支）-500%0%500%1000%0.050.0100.02014201520162017201820192020批签发量（折合250IU，万支）资料来源：wind，公司公告，东兴证券研究所医药行业研究p18东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研国产（折合100IU，按年）国产（折合100IU，按季度）国产份额（折合100IU，2020）2.8特免产品同比小幅下滑--乙型肝炎人免疫球蛋白-50%0%50%100%0.0200.0400.0600.020132014201520162017201820192020批签发量（折合100IU，万支）-200%-100%0%100%200%300%400%0.050.0100.0150.0200.0Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q3Q1Q320132014201520162017201820192020批签发量（折合100IU，万支）华兰生物,22.03%上海莱士,18.84%天坛生物,15.21%远大蜀阳药业,20.67%泰邦生物,12.15%南岳生物,7.69%博雅生物,3.40%➢2014-2019年，乙型肝炎人免疫球蛋白整体批签发量小幅下滑，由2014年289.6万支下降至2019年224.9万支，年均复合增速为-4.93%➢2020年全年，乙型肝炎人免疫球蛋白批签发216.3万支，同比-3.83%，其中Q1/Q2/Q3/Q4批签发量分别为50.1万支/27.3万支/68.3万支/70.7万支，同比增速分别为+279.02%/-71.24%/+276.03%/-28.37%➢2020年，共7家企业获得批签发，批签发量排名前5的企业为华兰生物、远大蜀阳、上海莱士、天坛生物、泰邦生物➢华兰生物批签发47.7万支，同比+86.24%，批签发份额22.0%，份额+10.66pct；天坛生物批签发32.9万支，同比-39.83%，批签发份额15.2%，份额-9.10pct；博雅生物批签发7.3万支。批签发份额3.4%，份额+3.4pct华兰生物（折合100IU，按年）天坛生物（折合100IU，按年）博雅生物（折合100IU，按年）-100%0%100%0.050.0100.02014201520162017201820192020批签发量（折合100IU，万支）-100%-50%0%50%100%0.020.040.060.02014201520162017201820192020批签发量（折合100IU，万支）0.05.010.015.020.02014201520162017201820192020批签发量（折合100IU，万支）资料来源：wind，公司公告，东兴证券研究所医药行业研究p19东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研➢国产人血白蛋白2020H2批签发下滑。2020年国产白蛋白批签发2102万支（-2.82%），2020年Q1/Q2/Q3/Q4国产白蛋白批签发量分别为529万支/530万支/621万支/422万支，同比增速分别为+11.0%/+3.6%/-2.7%/-21.3%。上半年全行业采浆量下滑约20%，结合投浆至产品滞后时间6-9个月，致H2批签发下滑明显。➢2021年国内采浆预计恢复性增长，带来产品销量增长弹性。2020年上半年全行业采浆量下滑约20%，自2020Q2后采浆量逐步恢复，判断2021年采浆量有望实现恢复性增长。浆量增长带来产品销量增长弹性。➢进口人血白蛋白下半年批签发亦有放缓。2020年进口批签发3835万支（+18.2%），2020Q1/Q2/Q3/Q4进口白蛋白批签发量分别为1012万支/1020万支/820万支/984万支,同比增速分别为+148.5%/+13.5%/-13.6%/-0.6%。➢基于海外疫情致采浆下滑，判断2021年进口白蛋白批签发放缓或将持续。海外疫情自3月爆发持续至今，当前美国疫情仍处于秋冬季节流行高峰，结合疫苗接种预期判断2021年疫情对采浆量影响持续，或将致2021年进口白蛋白批签发放缓持续。总结：2020基础上具备增量弹性，海外下滑有望推动价增医药行业研究p20东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研目录❑1.2020批签发：疫情影响国内采浆，下半年大品种批签发放缓❑2.2020年分品种批签发情况⚫人血白蛋白⚫静注人免疫球蛋白⚫人凝血酶原复合物⚫人纤维蛋白原⚫人凝血因子VIII⚫狂犬病人免疫球蛋白⚫破伤风人免疫球蛋白⚫乙型肝炎人免疫球蛋白❑3.2021年：短期出厂价有望提升，资源属性+需求提升稳定长期增长❑4.投资建议：关注行业龙头和浆量提升高弹性企业❑5.风险提示医药行业研究p21东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研短期：海外疫情可能影响人白进口•国内市场白蛋白进口产品超60%•海外疫情3月爆发并持续，3-10月美国采浆站滚动访问人次下滑50%•国际血制品巨头之一Grifols预计2020年财年采浆量-15%•国内诊疗秩序恢复，国内市场2021年白蛋白需求量较2020年恢复性增长•国内市场若出现白蛋白供给紧张，价格有望上行-80%-60%-40%-20%0%20%40%60%80%100%120%访问人次同比增速3月滚动访问人次增速图：海外疫情有望推动白蛋白价格上行资料来源：公司公告，东兴证券研究所图：2019-2020年美国采浆站访问人次同比增速资料来源：SafeGraph，东兴证券研究所图：全国医疗机构诊疗人次和出院人数资料来源：国家卫生健康委员会，东兴证券研究所-50%-40%-30%-20%-10%0%10%01000020000300004000050000600002月3月4月5月6月7月8月9月10月诊疗人次数（万人次）出院人数（万人）诊疗人次数同比增速出院人数同比增速医药行业研究p22东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研短期：判断2021疫情对海外采浆量的影响持续➢Grifols估计，2020财年COVID-19导致该公司血浆供应减少约15%➢CSL，2020财年采浆量-5%，2020Q2单季度采浆量下滑30%。预计2021财年疫情对采浆量的限制持续-50%-30%-10%10%30%50%0500001000001500002000002500003000003500002020-03-012020-03-162020-03-312020-04-152020-04-302020-05-152020-05-302020-06-142020-06-292020-07-142020-07-292020-08-132020-08-282020-09-122020-09-272020-10-122020-10-272020-11-112020-11-262020-12-112020-12-262021-01-10美国每日新增确诊病例数➢当前美国疫情仍处于秋冬季节流行高峰，新冠疫苗已获批在优先人群中紧急使用，预计2021年3月左右获正式批准上市，结合供应量和接种进度，疫苗接种周期预计持续2-3年，2021年底前将不会获得群体免疫➢结合海外血制企业反馈，2020Q2为采浆量低点，其后趋势上行，但疫情影响仍在，结合疫苗接种预期判断2021年疫情对采浆量影响持续企业类别交流时间疫情影响情况CSL血液制品生产商2020年8月2020财年采浆量下滑5%，其中2020年Q2下滑30%。2020年7-8月，采浆量趋势相较Q2上行，预计2021财年疫情对采浆量的限制持续Grifols血液制品生产商2020年9月2020财年采浆量下滑15%Takeda血液制品生产商2020年11月2020年春是采浆量的最低点，其后采浆量呈逐季度恢复趋势，但由于疫情持续，采浆仍然受到影响Haemonetics采浆仪器及耗材供应商2020年11月预计2020年Q3北美采浆量下滑约30%，预期采浆下滑趋势持续资料来源：wind，公司公告，东兴证券研究所医药行业研究p23东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研短期：美国血液制品分销量未见大幅下滑➢根据PPTA数据，美国白蛋白、血源性八因子等重点血液制品分销量3-6月出现调整后回归至均线以上水平，静丙分销量持续处于均线以上水平，判断核心血液制品使用量整体并未出现大幅下滑。采浆量下滑，美国本土分销量维持，或将加剧产品紧张。资料来源：PPTA，东兴证券研究所医药行业研究p24东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研长期：血液制品--资源属性+需求提升献浆员献浆单采血浆站血制品生产经销商医院药店患者产品常出现供不应求行业内竞争不激烈原料为人血浆01临床必需品种03市场需求提升趋势04行业监管严格02•2001年起不再新批血液制品企业，目前正常经营的血制品企业约17家•单采血浆站新设受到严格监管•血浆分离提纯得到白蛋白、免疫球蛋白、凝血因子等血液制品•血液制品在临床急救、疾病预防和治疗中具有不可替代的作用•我国人均血制品用量远低发达国家•白蛋白为美国1/3,静丙不足1/10供给端资源属性需求端提升趋势医药行业研究p25东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研长期：集采可行性低，医保控费背景下稳定•市场受采浆量约束：我国年采浆量约为9000吨，而测算需求浆量约1.4万吨，产品常供不应求；•单企业供应能力有限：企业供浆受各自采浆量约束，单个企业不具备大规模分割市场能力；•短缺风险：产品为临床必需，且短期无替代品，若纳入集采，一旦出现短缺，对诊疗机构冲击较大；020040060080010001200140016001800图：各血制品企业2019年采浆量（吨）资料来源：公司公告，东兴证券研究所图：白蛋白临床用药适应症分布资料来源：《基于文献计量学的国内人血白蛋白临床合理应用水平分析》.，东兴证券研究所图：我国2019年白蛋白批签发份额资料来源：中检院，东兴证券研究所医药行业研究p26东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研目录❑1.2020批签发：疫情影响国内采浆，下半年大品种批签发放缓❑2.2020年分品种批签发情况⚫人血白蛋白⚫静注人免疫球蛋白⚫人凝血酶原复合物⚫人纤维蛋白原⚫人凝血因子VIII⚫狂犬病人免疫球蛋白⚫破伤风人免疫球蛋白⚫乙型肝炎人免疫球蛋白❑3.2021年：短期出厂价有望提升，资源属性+需求提升稳定长期增长❑4.投资建议：关注行业龙头和浆量提升高弹性企业❑5.风险提示医药行业研究p27东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研关注行业龙头和浆量提升高弹性企业➢2021年短期看白蛋白进入提价窗口期，长期看资源属性+需求稳步提升1）短期：国内血液制品有望实现量价齐升。①价：预计2021年初进入白蛋白提价的窗口期；②量：2021年采浆量恢复性增长+外延扩大供给弹性2）长期：①血制品行业壁垒高，具备资源品属性；②需求量相比发达国家具备增长空间；③集采可行性低，医保控费背景下行业稳定。采浆量稳步提升推动行业稳定增长➢投资建议：从市场份额与产能提升潜力进行筛选，建议关注行业龙头和浆量提升高弹性企业：其中龙头企业更具备定价权，提价更占据主动；在进口供应短缺阶段，更具备产能供给弹性的企业有望抢占更多市场的份额1）行业龙头企业：天坛生物（600161），①浆量：浆站持续开拓，浆站数和浆量均领跑行业，伴随各省十四五规划出台，有望发挥国资优势继续扩展浆站资源；②品种：新品研发推进，蓉生人凝血酶原复合物获批，八因子、层析静丙、纤原等品种逐步推进，产品线拓展推动吨浆利润提升；③产能：产能瓶颈突破，永安血制、云南血制、兰州血制项目顺利推进，项目投产后产能扩大至接近5k吨华兰生物（002007），①浆量：行业千吨血制龙头；②品种：批签发品种齐全，品种数居行业前列；③吨浆收入、吨浆利润等指标均领跑行业。公司采浆量和产品线有望进一步扩大，推动血制业务盈利提升2）浆量提升高弹性企业：双林生物（000403），派斯菲科整合+新疆德源调浆，有望步入千吨梯队。①2019年公司采浆量超400吨，2022年公司本部采浆量有望达600吨；②派斯菲科2019年采浆240吨，后续采浆量有望突破500吨；③新疆德源5年内每年为公司供浆180吨以上。公司浆量将达千吨，采浆规模大幅提升有望带来显著规模效益博雅生物（300294），①华润入主，打造华润系内长期的血液制品发展平台；②公司依托央企资源，获得有力资金支持、政府事务能力支持、并购整合能力支持，取得竞争优势；③有望借助博雅（广东）血浆调拨及后续整合步入千吨血制梯队医药行业研究p28东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研天坛生物-100%-50%0%50%100%0.010.020.030.040.050.012345678910111220192020月度同比增速人血白蛋白（折合10g，按月）-100%-50%0%50%100%0.020.040.060.012345678910111220192020月度同比增速静注人免疫球蛋白（折合2.5g，按月）➢2020年全年，天坛生物批签发白蛋白433万支（+0.3%）、静丙312万支（+6.38%）、八因子0.4万支（新增批签发）、狂免66.7万支（-40.35%）、破免96.2万支（-30.72%）、乙免32.9万支（-39.83%）狂犬病人免疫球蛋白（折合200IU，按月）乙肝人免疫球蛋白（折合100IU，按月）破伤风人免疫球蛋白（折合250IU，按月）0.010.020.030.040.0123456789101112201920200.05.010.015.020.025.030.0123456789101112201920200.05.010.015.020.025.030.012345678910111220192020资料来源：wind，公司公告，东兴证券研究所2020Q1Q2Q3收入同比（%）7.36-6.7212.71归母净利润同比（%）0.27-6.3623.054.626.42天坛生物业绩回顾Q1-3医药行业研究p29东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研华兰生物➢2020年全年，华兰生物批签发白蛋白245万支（-16.87%）、静丙138万支（-24.33%）、PCC55.3万支（+28.50%）、八因子48.2万支（-23.38%）、狂免99.2万支（-21.18%）、破免165.6万支（-0.22%）、乙免47.7万支（+86.24%）人血白蛋白（折合10g，按月）静注人免疫球蛋白（折合2.5g，按月）人凝血因子VIII（折合200IU，按月）人凝血酶原复合物（折合200IU，按月）-100%-50%0%50%100%0.010.020.030.040.050.012345678910111220192020月度同比增速-100%-50%0%50%100%0.010.020.030.040.012345678910111220192020月度同比增速-100%-50%0%50%100%150%200%250%0.02.04.06.08.010.012.012345678910111220192020同比增速-200%-100%0%100%200%300%400%0.05.010.015.020.012345678910111220192020同比增速资料来源：wind，公司公告，东兴证券研究所2020Q1Q2Q3收入同比(%)-2.620.3136.45归母净利润同比（%）-6.7510.018.68Q1-316.460.04华兰生物业绩回顾医药行业研究p30东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研华兰生物➢2020年全年，华兰生物批签发白蛋白245万支（-16.87%）、静丙138万支（-24.33%）、PCC55.3万支（+28.50%）、八因子48.2万支（-23.38%）、狂免99.2万支（-21.18%）、破免165.6万支（-0.22%）、乙免47.7万支（+86.24%）狂犬病人免疫球蛋白（折合200IU，按月）乙肝人免疫球蛋白（折合100IU，按月）破伤风人免疫球蛋白（折合250IU，按月）-200%-100%0%100%200%300%400%0.05.010.015.020.025.030.035.040.012345678910111220192020同比增速-150%-100%-50%0%50%100%150%200%250%0.010.020.030.040.050.012345678910111220192020同比增速-120%-100%-80%-60%-40%-20%0%20%40%0.05.010.015.020.025.012345678910111220192020同比增速资料来源：wind，公司公告，东兴证券研究所2020Q1Q2Q3收入同比(%)-2.620.3136.45归母净利润同比（%）-6.7510.018.68Q1-316.460.04华兰生物业绩回顾医药行业研究p31东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研双林生物➢2020年全年，双林生物批签发白蛋白118万支（-3.38%）、静丙69万支（+29.01%）、狂免134.1万支（-12.84%）、破免72.5万支（+36.98%）人血白蛋白（折合10g，按月）静注人免疫球蛋白（折合2.5g，按月）狂犬病人免疫球蛋白（折合200IU，按月）破伤风人免疫球蛋白（折合250IU，按月）-150%-100%-50%0%50%100%150%0.05.010.015.020.025.012345678910111220192020月度同比增速-200%0%200%400%600%800%0.05.010.015.020.012345678910111220192020月度同比增速0.010.020.030.040.012345678910111220192020-150%-100%-50%0%50%100%150%0.05.010.015.012345678910111220192020同比增速资料来源：wind，公司公告，东兴证券研究所2020Q1Q2Q3　　　　收入同比(%)18.8-3.55-1.59归母净利润同比（%）3.57-29-17.8Q1-33.36-18.50双林生物业绩回顾医药行业研究p32东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研博雅生物➢2020年全年，博雅生物批签发白蛋白90万支（+4.49%）、静丙65万支（+12.12%）、纤原26.3万支（-3.58%）、狂免80.6万支（+22.93%）、乙免7.3万支（去年同期无批签发）人血白蛋白（折合10g，按月）静注人免疫球蛋白（折合2.5g，按月）人纤维蛋白原（折合0.5g，按月）狂犬病人免疫球蛋白（折合200IU，按月）-200%0%200%400%600%800%1000%0.05.010.015.012345678910111220192020月度同比增速-120%-100%-80%-60%-40%-20%0%0.05.010.015.012345678910111220192020同比增速-120%-100%-80%-60%-40%-20%0%20%0.02.04.06.08.010.012345678910111220192020同比增速-200%-100%0%100%200%300%400%500%0.05.010.015.020.025.012345678910111220192020月度同比增速资料来源：wind，公司公告，东兴证券研究所2020Q1Q2Q3　　　　收入同比(%)-0.11-6.5-9.03归母净利润同比（%）8.25-46.76-39.03Q1-3-5.39-29.69博雅生物业绩回顾医药行业研究p33东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研白蛋白提价收入弹性测算➢测算假设：取2020年批签发量为销量测算基础，假设2021年销售量同比增幅0%~+30%之间；假设白蛋白（10g/瓶）出厂价提价幅度分别取30元、40元、50元、60元测算（+10%~+20%）➢若白蛋白销量同比增长10%，白蛋白提价幅度+40元/瓶，天坛生物、华兰生物、博雅生物、双林生物由白蛋白提价所带来的营业收入增长分别为1.9亿元（+5.52%）、1.08亿元（+2.43%）、0.40亿元（+1.52%）、0.52亿元（+5.37%）资料来源：wind，公司公告，东兴证券研究所医药行业研究p34东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研目录❑1.2020批签发：疫情影响国内采浆，下半年大品种批签发放缓❑2.2020年分品种批签发情况⚫人血白蛋白⚫静注人免疫球蛋白⚫人凝血酶原复合物⚫人纤维蛋白原⚫人凝血因子VIII⚫狂犬病人免疫球蛋白⚫破伤风人免疫球蛋白⚫乙型肝炎人免疫球蛋白❑3.2021年：短期出厂价有望提升，资源属性+需求提升稳定长期增长❑4.投资建议：关注行业龙头和浆量提升高弹性企业❑5.风险提示医药行业研究p35东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研风险提示相关报告汇总报告类型标题日期公司报告博雅生物（300294.SZ）：业绩短期承压，华润入主打造央企长期血制平台2020-10-30公司报告天坛生物（600161.SH）：Q3业绩高增，定增募资促长期增长2020-10-30公司报告双林生物（000403.SZ）：上半年业绩符合预期，浆源和品种拓展可期2020-08-31公司报告双林生物（000403.SZ）：收购派斯菲科，浆源和品种拓展迎发展新阶段2020-05-18公司报告上海莱士（002252.SZ）：GDS收购落地，基立福持股促长远发展2020-05-11公司报告天坛生物（600161.SH）：19年业绩稳步增长，新品研发和产能扩展强化规模优势2020-04-03公司报告华兰生物（002007.SZ）：年报业绩符合预期，血制品景气提升及四价苗放量可期2020-03-25资料来源：东兴证券研究所风险提示：浆站采浆量不及预期，产品销售不达预期，新品研发进展不及预期，产品潜在安全性风险。医药行业研究p36东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研分析师简介胡博新药学专业，10年证券行业医药研究经验，曾在医药新财富团队担任核心成员。对原料药、医疗器械、血液制品行业有长期跟踪经验。研究助理简介王敏杰中央财经大学金融硕士，中山大学医学学士。2019年7月加入东兴证券，从事医药行业研究。医药行业研究p37东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研分析师承诺负责本研究报告全部或部分内容的每一位证券分析师，在此申明，本报告的观点、逻辑和论据均为分析师本人研究成果，引用的相关信息和文字均已注明出处。本报告依据公开的信息来源，力求清晰、准确地反映分析师本人的研究观点。本人薪酬的任何部分过去不曾与、现在不与，未来也将不会与本报告中的具体推荐或观点直接或间接相关。风险提示本证券研究报告所载的信息、观点、结论等内容仅供投资者决策参考。在任何情况下，本公司证券研究报告均不构成对任何机构和个人的投资建议，市场有风险，投资者在决定投资前，务必要审慎。投资者应自主作出投资决策，自行承担投资风险。医药行业研究p38东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研免责声明本研究报告由东兴证券股份有限公司研究所撰写，东兴证券股份有限公司是具有合法证券投资咨询业务资格的机构。本研究报告中所引用信息均来源于公开资料，我公司对这些信息的准确性和完整性不作任何保证，也不保证所包含的信息和建议不会发生任何变更。我们已力求报告内容的客观、公正，但文中的观点、结论和建议仅供参考，报告中的信息或意见并不构成所述证券的买卖出价或征价，投资者据此做出的任何投资决策与本公司和作者无关。我公司及其所属关联机构可能会持有报告中提到的公司所发行的证券头寸并进行交易，也可能为这些公司提供或者争取提供投资银行、财务顾问或者金融产品等相关服务。本报告版权仅为我公司所有，未经书面许可，任何机构和个人不得以任何形式翻版、复制和发布。如引用、刊发，需注明出处为东兴证券研究所，且不得对本报告进行有悖原意的引用、删节和修改。本研究报告仅供东兴证券股份有限公司客户和经本公司授权刊载机构的客户使用，未经授权私自刊载研究报告的机构以及其阅读和使用者应慎重使用报告、防止被误导，本公司不承担由于非授权机构私自刊发和非授权客户使用该报告所产生的相关风险和责任。医药行业研究p39东方财智兴盛之源东兴证券股份有限公司证券研究报告：医药行业研行业评级体系公司投资评级（以沪深300指数为基准指数）：以报告日后的6个月内，公司股价相对于同期市场基准指数的表现为标准定义：强烈推荐：相对强于市场基准指数收益率15％以上；推荐：相对强于市场基准指数收益率5％～15％之间；中性：相对于市场基准指数收益率介于-5％～+5％之间；回避：相对弱于市场基准指数收益率5％以上。行业投资评级（以沪深300指数为基准指数）：以报告日后的6个月内，行业指数相对于同期市场基准指数的表现为标准定义：看好：相对强于市场基准指数收益率5％以上；中性：相对于市场基准指数收益率介于-5％～+5％之间；看淡：相对弱于市场基准指数收益率5％以上。前沿报告库是中国新经济产业咨询报告共享平台。行业范围涵盖新一代信息技术、5G、物联网、新能源、新材料、新消费、大健康、大数据、智能制造等新兴领域。为企事业单位、科研院所、投融资机构等提供研究和决策参考。扫一扫免费获取海量报告","data":[{"id":"1","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"白蛋白：2020年全年白蛋白批签发总量5938万支（+9.8%）","content_offset":["272","304"],"indicators":[{"indicator_name":"批签发量","indicator_value":["5938万支","291","297"],"indicator_element":{"时间":["2020年全年","276","283"],"产品":["白蛋白","272","275"]},"indicator_supplement":{"属性":""}}]},{"id":"2","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"白蛋白：2020年全年白蛋白批签发总量5938万支（+9.8%）","content_offset":["272","304"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+9.8%","298","303"],"indicator_element":{"时间":["2020年全年","276","283"],"产品":["白蛋白","272","275"]},"indicator_supplement":{"属性":""}}]},{"id":"3","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"其中国产批签发2102万支（-2.82%）","content_offset":["305","326"],"indicators":[{"indicator_name":"批签发量","indicator_value":["102万支","313","318"],"indicator_element":{"时间":["2020年全年","276","283"],"产品":["白蛋白","261","264"],"渠道":["国产","307","309"]},"indicator_supplement":{"属性":""}}]},{"id":"4","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"其中国产批签发2102万支（-2.82%）","content_offset":["305","326"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-2.82%","319","325"],"indicator_element":{"时间":["2020年全年","276","283"],"产品":["白蛋白","261","264"],"渠道":["国产","307","309"]},"indicator_supplement":{"属性":""}}]},{"id":"5","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"进口批签发3835万支（+18.2%）","content_offset":["327","346"],"indicators":[{"indicator_name":"批签发量","indicator_value":["3835万支","332","338"],"indicator_element":{"时间":["2020年全年","276","283"],"产品":["白蛋白","261","264"],"渠道":["进口","327","329"]},"indicator_supplement":{"属性":""}}]},{"id":"6","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"进口批签发3835万支（+18.2%）","content_offset":["327","346"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+18.2%","339","345"],"indicator_element":{"时间":["2020年全年","276","283"],"产品":["白蛋白","261","264"],"渠道":["进口","327","329"]},"indicator_supplement":{"属性":""}}]},{"id":"7","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"静丙：2020年全年，静注人免疫球蛋白批签发1321万支","content_offset":["389","417"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1321万支","411","417"],"indicator_element":{"时间":["2020年全年","392","399"],"产品":["静丙","389","391"]},"indicator_supplement":{"属性":""}}]},{"id":"8","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"同比增长7.17%","content_offset":["418","427"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["7.17%","422","427"],"indicator_element":{"时间":["2020年全年","392","399"],"产品":["静丙","389","391"]},"indicator_supplement":{"属性":""}}]},{"id":"9","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2020年Q1受疫情需求推动，静丙批签发大幅增长（+100.57%）","content_offset":["428","462"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+100.57%","453","461"],"indicator_element":{"时间":["2020年Q1","428","435"],"产品":["静丙","443","445"]},"indicator_supplement":{"属性":""}}]},{"id":"10","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"人血白蛋白：折合10g规格，进口+国产（5938万支，同比+9.8%）","content_offset":["1243","1278"],"indicators":[{"indicator_name":"批签发量","indicator_value":["5938万支","1263","1269"],"indicator_element":{"时间":["2020年","1444","1449"],"产品":["人血白蛋白","1243","1248"],"渠道":["国产","1260","1262"]},"indicator_supplement":{"属性":""}}]},{"id":"11","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"人血白蛋白：折合10g规格，进口+国产（5938万支，同比+9.8%）","content_offset":["1243","1278"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+9.8%","1272","1277"],"indicator_element":{"时间":["2020年","1444","1449"],"产品":["人血白蛋白","1243","1248"],"渠道":["国产","1260","1262"]},"indicator_supplement":{"属性":""}}]},{"id":"12","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"国产（2102万支，同比-2.82%）","content_offset":["1279","1298"],"indicators":[{"indicator_name":"批签发量","indicator_value":["2102万支","1282","1288"],"indicator_element":{"时间":["2020年","1444","1449"],"产品":["人血白蛋白","1243","1248"],"渠道":["国产","1279","1281"]},"indicator_supplement":{"属性":""}}]},{"id":"13","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"国产（2102万支，同比-2.82%）","content_offset":["1279","1298"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-2.82%","1291","1297"],"indicator_element":{"时间":["2020年","1444","1449"],"产品":["人血白蛋白","1243","1248"],"渠道":["国产","1279","1281"]},"indicator_supplement":{"属性":""}}]},{"id":"14","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"静注人免疫球蛋白：折合2.5g规格，整体（1321万支，同比+7.2%），","content_offset":["1353","1390"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1321万支","1374","1380"],"indicator_element":{"时间":["2020年","1444","1449"],"产品":["静注人免疫球蛋白","1353","1361"]},"indicator_supplement":{"属性":""}}]},{"id":"15","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"静注人免疫球蛋白：折合2.5g规格，整体（1321万支，同比+7.2%），","content_offset":["1353","1390"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+7.2%","1383","1388"],"indicator_element":{"时间":["2020年","1444","1449"],"产品":["静注人免疫球蛋白","1353","1361"]},"indicator_supplement":{"属性":""}}]},{"id":"16","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"人纤维蛋白原：折合0.5g规格，整体（139.9万支，同比+66.3%）","content_offset":["2952","2988"],"indicators":[{"indicator_name":"批签发量","indicator_value":["139.9万支","2971","2978"],"indicator_element":{"时间":["2020年","3310","3315"],"产品":["人纤维蛋白原","2952","2958"]},"indicator_supplement":{"属性":""}}]},{"id":"17","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"人纤维蛋白原：折合0.5g规格，整体（139.9万支，同比+66.3%）","content_offset":["2952","2988"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+66.3%","2981","2987"],"indicator_element":{"时间":["2020年","3310","3315"],"产品":["人纤维蛋白原","2952","2958"]},"indicator_supplement":{"属性":""}}]},{"id":"18","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"人凝血酶原复合物：折合200IU规格，整体（151.6万支，同比+59.5%）","content_offset":["3008","3047"],"indicators":[{"indicator_name":"批签发量","indicator_value":["151.6万支","3030","3037"],"indicator_element":{"时间":["2020年","3310","3315"],"产品":["人凝血酶原复合物","3008","3016"]},"indicator_supplement":{"属性":""}}]},{"id":"19","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"人凝血酶原复合物：折合200IU规格，整体（151.6万支，同比+59.5%）","content_offset":["3008","3047"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+59.5%","3040","3046"],"indicator_element":{"时间":["2020年","3310","3315"],"产品":["人凝血酶原复合物","3008","3016"]},"indicator_supplement":{"属性":""}}]},{"id":"20","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"人凝血因子VIII：折合200IU规格，整体（198.4万支，同比+14.4%）","content_offset":["3068","3108"],"indicators":[{"indicator_name":"批签发量","indicator_value":["198.4万支","3091","3098"],"indicator_element":{"时间":["2020年","3310","3315"],"产品":["人凝血因子VIII","3068","3077"]},"indicator_supplement":{"属性":""}}]},{"id":"21","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"人凝血因子VIII：折合200IU规格，整体（198.4万支，同比+14.4%）","content_offset":["3068","3108"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+14.4%","3101","3107"],"indicator_element":{"时间":["2020年","3310","3315"],"产品":["人凝血因子VIII","3068","3077"]},"indicator_supplement":{"属性":""}}]},{"id":"22","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"狂犬病人免疫球蛋白：折合200IU规格，整体（1169.8万支，同比-7.9%）","content_offset":["3129","3169"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1169.8万支","3152","3160"],"indicator_element":{"时间":["2020年","3310","3315"],"产品":["狂犬病人免疫球蛋白","3129","3138"]},"indicator_supplement":{"属性":""}}]},{"id":"23","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"狂犬病人免疫球蛋白：折合200IU规格，整体（1169.8万支，同比-7.9%）","content_offset":["3129","3169"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-7.9%","3163","3168"],"indicator_element":{"时间":["2020年","3310","3315"],"产品":["狂犬病人免疫球蛋白","3129","3138"]},"indicator_supplement":{"属性":""}}]},{"id":"24","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"破伤风人免疫球蛋白：折合250IU规格，整体（618.4万支，同比-6.2%）","content_offset":["3190","3229"],"indicators":[{"indicator_name":"批签发量","indicator_value":["618.4万支","3213","3220"],"indicator_element":{"时间":["2020年","3310","3315"],"产品":["破伤风人免疫球蛋白","3190","3199"]},"indicator_supplement":{"属性":""}}]},{"id":"25","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"破伤风人免疫球蛋白：折合250IU规格，整体（618.4万支，同比-6.2%）","content_offset":["3190","3229"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-6.2%","3223","3228"],"indicator_element":{"时间":["2020年","3310","3315"],"产品":["破伤风人免疫球蛋白","3190","3199"]},"indicator_supplement":{"属性":""}}]},{"id":"26","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"乙型肝炎人免疫球蛋白：折合100IU规格，整体（216.3万支，同比-3.8%）","content_offset":["3250","3290"],"indicators":[{"indicator_name":"批签发量","indicator_value":["216.3万支","3274","3281"],"indicator_element":{"时间":["2020年","3310","3315"],"产品":["乙型肝炎人免疫球蛋白","3250","3260"]},"indicator_supplement":{"属性":""}}]},{"id":"27","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"乙型肝炎人免疫球蛋白：折合100IU规格，整体（216.3万支，同比-3.8%）","content_offset":["3250","3290"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-3.8%","3284","3289"],"indicator_element":{"时间":["2020年","3310","3315"],"产品":["乙型肝炎人免疫球蛋白","3250","3260"]},"indicator_supplement":{"属性":""}}]},{"id":"28","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2014-2020年，白蛋白批签发总量平稳增长，年均复合增速约为+12.89%","content_offset":["5464","5503"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["+12.89%","5496","5503"],"indicator_element":{"时间":["2014-2020年","5464","5474"],"产品":["白蛋白","5475","5478"]},"indicator_supplement":{"属性":""}}]},{"id":"29","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2020年全年批签发总量5938万支（+9.8%）","content_offset":["5504","5529"],"indicators":[{"indicator_name":"批签发量","indicator_value":["5938万支","5516","5522"],"indicator_element":{"时间":["2020年全年","5504","5511"],"产品":["白蛋白","5440","5443"]},"indicator_supplement":{"属性":""}}]},{"id":"30","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2020年全年批签发总量5938万支（+9.8%）","content_offset":["5504","5529"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+9.8%","5523","5528"],"indicator_element":{"时间":["2020年全年","5504","5511"],"产品":["白蛋白","5440","5443"]},"indicator_supplement":{"属性":""}}]},{"id":"31","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"其中国产批签发2102万支（-2.82%）","content_offset":["305","326"],"indicators":[{"indicator_name":"批签发量","indicator_value":["2102万支","312","318"],"indicator_element":{"时间":["2020年全年","276","283"],"产品":["白蛋白","261","264"],"渠道":["国产","307","309"]},"indicator_supplement":{"属性":""}}]},{"id":"32","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"其中国产批签发2102万支（-2.82%）","content_offset":["305","326"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-2.82%","319","325"],"indicator_element":{"时间":["2020年全年","276","283"],"产品":["白蛋白","261","264"],"渠道":["国产","307","309"]},"indicator_supplement":{"属性":""}}]},{"id":"33","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"进口批签发3835万支（+18.2%）","content_offset":["327","346"],"indicators":[{"indicator_name":"批签发量","indicator_value":["3835万支","332","338"],"indicator_element":{"时间":["2020年全年","276","283"],"产品":["白蛋白","261","264"],"渠道":["进口","327","329"]},"indicator_supplement":{"属性":""}}]},{"id":"34","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"进口批签发3835万支（+18.2%）","content_offset":["327","346"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+18.2%","339","345"],"indicator_element":{"时间":["2020年全年","276","283"],"产品":["白蛋白","261","264"],"渠道":["进口","327","329"]},"indicator_supplement":{"属性":""}}]},{"id":"35","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2020年Q1/Q2/Q3/Q4国产白蛋白批签发量分别为529万支/530万支/621万支/422万支","content_offset":["5684","5735"],"indicators":[{"indicator_name":"批签发量","indicator_value":["529万支","5712","5717"],"indicator_element":{"时间":["2020年Q1/Q2/Q3/Q4","5684","5700"],"产品":["白蛋白","5702","5705"],"渠道":["国产","5700","5702"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["530万支","5718","5723"],"indicator_element":{"时间":["2020年Q1/Q2/Q3/Q4","5684","5700"],"产品":["白蛋白","5702","5705"],"渠道":["国产","5700","5702"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["621万支","5724","5729"],"indicator_element":{"时间":["2020年Q1/Q2/Q3/Q4","5684","5700"],"产品":["白蛋白","5702","5705"],"渠道":["国产","5700","5702"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["422万支","5730","5735"],"indicator_element":{"时间":["2020年Q1/Q2/Q3/Q4","5684","5700"],"产品":["白蛋白","5702","5705"],"渠道":["国产","5700","5702"]},"indicator_supplement":{"属性":""}}]},{"id":"36","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"同比增速分别为+11.0%/+3.6%/-2.7%/-21.3%","content_offset":["5736","5768"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+11.0%","5743","5749"],"indicator_element":{"时间":["2020年Q1/Q2/Q3/Q4","5684","5700"],"产品":["白蛋白","5666","5669"],"渠道":["国产","5700","5702"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["+3.6%","5750","5755"],"indicator_element":{"时间":["2020年Q1/Q2/Q3/Q4","5684","5700"],"产品":["白蛋白","5666","5669"],"渠道":["国产","5700","5702"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-2.7%","5756","5761"],"indicator_element":{"时间":["2020年Q1/Q2/Q3/Q4","5684","5700"],"产品":["白蛋白","5666","5669"],"渠道":["国产","5700","5702"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-21.3%","5762","5768"],"indicator_element":{"时间":["2020年Q1/Q2/Q3/Q4","5684","5700"],"产品":["白蛋白","5666","5669"],"渠道":["国产","5700","5702"]},"indicator_supplement":{"属性":""}}]},{"id":"37","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2020Q1/Q2/Q3/Q4进口白蛋白批签发量分别为1012万支/1020万支/820万支/984万支","content_offset":["5822","5874"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1012万支","5849","5855"],"indicator_element":{"时间":["2020年Q1/Q2/Q3/Q4","6299","6315"],"产品":["白蛋白","5839","5842"],"渠道":["进口","5837","5839"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["1020万支","5856","5862"],"indicator_element":{"时间":["2020年Q1/Q2/Q3/Q4","6299","6315"],"产品":["白蛋白","5839","5842"],"渠道":["进口","5837","5839"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["820万支","5863","5868"],"indicator_element":{"时间":["2020年Q1/Q2/Q3/Q4","6299","6315"],"产品":["白蛋白","5839","5842"],"渠道":["进口","5837","5839"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["984万支","5869","5874"],"indicator_element":{"时间":["2020年Q1/Q2/Q3/Q4","6299","6315"],"产品":["白蛋白","5839","5842"],"渠道":["进口","5837","5839"]},"indicator_supplement":{"属性":""}}]},{"id":"38","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"同比增速分别为+148.5%/+13.5%/-13.6%/-0.6%","content_offset":["5875","5909"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+148.5%","5882","5889"],"indicator_element":{"时间":["2020年Q1/Q2/Q3/Q4","6299","6315"],"产品":["白蛋白","5784","5787"],"渠道":["进口","5782","5784"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["+13.5%","5890","5896"],"indicator_element":{"时间":["2020年Q1/Q2/Q3/Q4","6299","6315"],"产品":["白蛋白","5784","5787"],"渠道":["进口","5782","5784"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-13.6%","5897","5903"],"indicator_element":{"时间":["2020年Q1/Q2/Q3/Q4","6299","6315"],"产品":["白蛋白","5784","5787"],"渠道":["进口","5782","5784"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-0.6%","5904","5909"],"indicator_element":{"时间":["2020年Q1/Q2/Q3/Q4","6299","6315"],"产品":["白蛋白","5784","5787"],"渠道":["进口","5782","5784"]},"indicator_supplement":{"属性":""}}]},{"id":"39","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2014-2019年国产白蛋白和进口白蛋白批签发比例相对稳定，其中国产白蛋白批签发占比约40%-43%","content_offset":["6184","6235"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["40%-43%","6228","6235"],"indicator_element":{"时间":["2014-2019年","6184","6194"],"产品":["白蛋白","6196","6199"],"渠道":["国产","6194","6196"]},"indicator_supplement":{"属性":""}}]},{"id":"40","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2020年Q1/Q2/Q3/Q4国产批签发占比分别为34%/34%/43%/30%","content_offset":["6299","6340"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["34%","6325","6328"],"indicator_element":{"时间":["2020年Q1/Q2/Q3/Q4","6299","6315"],"产品":["白蛋白","6202","6205"],"渠道":["国产","6315","6317"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量占比","indicator_value":["34%","6325","6328"],"indicator_element":{"时间":["2020年Q1/Q2/Q3/Q4","6299","6315"],"产品":["白蛋白","6202","6205"],"渠道":["国产","6315","6317"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量占比","indicator_value":["43%","6333","6336"],"indicator_element":{"时间":["2020年Q1/Q2/Q3/Q4","6299","6315"],"产品":["白蛋白","6202","6205"],"渠道":["国产","6315","6317"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量占比","indicator_value":["30%","6337","6340"],"indicator_element":{"时间":["2020年Q1/Q2/Q3/Q4","6299","6315"],"产品":["白蛋白","6202","6205"],"渠道":["国产","6315","6317"]},"indicator_supplement":{"属性":""}}]},{"id":"41","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"进口白蛋白批签发占比分别为66%/66%/57%/70%","content_offset":["6341","6369"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["66%","6354","6357"],"indicator_element":{"时间":["2020年Q1/Q2/Q3/Q4","6299","6315"],"产品":["白蛋白","6343","6346"],"渠道":["进口","6341","6343"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量占比","indicator_value":["66%","6354","6357"],"indicator_element":{"时间":["2020年Q1/Q2/Q3/Q4","6299","6315"],"产品":["白蛋白","6343","6346"],"渠道":["进口","6341","6343"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量占比","indicator_value":["57%","6362","6365"],"indicator_element":{"时间":["2020年Q1/Q2/Q3/Q4","6299","6315"],"产品":["白蛋白","6343","6346"],"渠道":["进口","6341","6343"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量占比","indicator_value":["50%","6673","6676"],"indicator_element":{"时间":["2020年Q1/Q2/Q3/Q4","6299","6315"],"产品":["白蛋白","6343","6346"],"渠道":["进口","6341","6343"]},"indicator_supplement":{"属性":""}}]},{"id":"42","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2020年全年，国产白蛋白批签发占比降至35.4%","content_offset":["6370","6395"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["降至35.4%","6388","6395"],"indicator_element":{"时间":["2020年全年","6370","6377"],"产品":["白蛋白","6380","6383"],"渠道":["国产","6378","6380"]},"indicator_supplement":{"属性":""}}]},{"id":"43","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"进口白蛋白批签发占比增至64.6%","content_offset":["6396","6413"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["增至64.6%","6406","6413"],"indicator_element":{"时间":["2020年全年","6370","6377"],"产品":["白蛋白","6398","6401"],"渠道":["进口","6396","6398"]},"indicator_supplement":{"属性":""}}]},{"id":"44","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2014-2020年，静注人免疫球蛋白（含冻干静注人免疫球蛋白，下同）批签发量年均复合增长约+10.96%","content_offset":["9324","9377"],"indicators":[{"indicator_name":"批签发量","indicator_value":["+10.96%","9370","9377"],"indicator_element":{"时间":["2014-2020年","9324","9334"],"产品":["静注人免疫球蛋白","9335","9343"]},"indicator_supplement":{"属性":""}}]},{"id":"45","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2020年全年，静注人免疫球蛋白折算后批签发1321万支","content_offset":["9378","9406"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1321万支","9400","9406"],"indicator_element":{"时间":["2020年全年","9378","9385"],"产品":["静注人免疫球蛋白","9386","9394"]},"indicator_supplement":{"属性":""}}]},{"id":"46","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"同比增长7.17%","content_offset":["418","427"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["增长7.17%","420","427"],"indicator_element":{"时间":["2020年全年","392","399"],"产品":["静注人免疫球蛋白","400","408"]},"indicator_supplement":{"属性":""}}]},{"id":"47","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2020年Q1受疫情需求推动，静丙批签发大幅增长（+100.57%）","content_offset":["428","462"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+100.57%","453","461"],"indicator_element":{"时间":["2020年Q1","428","435"],"产品":["静注人免疫球蛋白","400","408"]},"indicator_supplement":{"属性":""}}]},{"id":"48","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"Q2/Q3/Q4同比增速分别为+3.07%/-30.86%/-3.90%","content_offset":["9521","9557"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+3.07%","9536","9542"],"indicator_element":{"时间":["2020年Q2/Q3/Q4","-1","-1"],"产品":["静注人免疫球蛋白","16806","16814"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-30.86%","9543","9550"],"indicator_element":{"时间":["2020年Q2/Q3/Q4","-1","-1"],"产品":["静注人免疫球蛋白","16806","16814"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-3.90%","9551","9557"],"indicator_element":{"时间":["2020年Q2/Q3/Q4","-1","-1"],"产品":["静注人免疫球蛋白","16806","16814"]},"indicator_supplement":{"属性":""}}]},{"id":"52","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"其中人凝血酶原复合物2014-2020年批签发量年均复合增速约为+17.23%","content_offset":["10769","10808"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["+17.23%","10801","10808"],"indicator_element":{"时间":["2014-2020年","10779","10789"],"产品":["人凝血酶原复合物","10771","10779"]},"indicator_supplement":{"属性":""}}]},{"id":"53","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2020年全年，人凝血酶原复合物整体批签发151.6万支","content_offset":["10809","10837"],"indicators":[{"indicator_name":"批签发量","indicator_value":["151.6万支","10830","10837"],"indicator_element":{"时间":["2020年全年","10809","10816"],"产品":["人凝血酶原复合物","10817","10825"]},"indicator_supplement":{"属性":""}}]},{"id":"54","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"同比+59.54%","content_offset":["10838","10847"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+59.54%","10840","10847"],"indicator_element":{"时间":["2020年全年","10809","10816"],"产品":["人凝血酶原复合物","10771","10779"]},"indicator_supplement":{"属性":""}}]},{"id":"55","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"其中Q1/Q2/Q3/Q4批签发量分别为36.0万支/48.3万支/31.8万支/35.4万支","content_offset":["10848","10895"],"indicators":[{"indicator_name":"批签发量","indicator_value":["36.0万支","10868","10874"],"indicator_element":{"时间":["Q1/Q2/Q3/Q4","10850","10861"],"产品":["人凝血酶原复合物","10771","10779"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["8.3万支","10876","10881"],"indicator_element":{"时间":["Q1/Q2/Q3/Q4","10850","10861"],"产品":["人凝血酶原复合物","10771","10779"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["31.8万支","10882","10888"],"indicator_element":{"时间":["Q1/Q2/Q3/Q4","10850","10861"],"产品":["人凝血酶原复合物","10771","10779"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["35.4万支","10889","10895"],"indicator_element":{"时间":["Q1/Q2/Q3/Q4","10850","10861"],"产品":["人凝血酶原复合物","10771","10779"]},"indicator_supplement":{"属性":""}}]},{"id":"56","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"同比增速分别为+260.26%/+93.55%/-15.73%/+58.93%","content_offset":["10896","10935"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+260.26%","10903","10911"],"indicator_element":{"时间":["Q1/Q2/Q3/Q4","10850","10861"],"产品":["人凝血酶原复合物","10817","10825"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["+93.55%","10912","10919"],"indicator_element":{"时间":["Q1/Q2/Q3/Q4","10850","10861"],"产品":["人凝血酶原复合物","10817","10825"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-15.73%","10920","10927"],"indicator_element":{"时间":["Q1/Q2/Q3/Q4","10850","10861"],"产品":["人凝血酶原复合物","10817","10825"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["+58.93%","10928","10935"],"indicator_element":{"时间":["Q1/Q2/Q3/Q4","10850","10861"],"产品":["人凝血酶原复合物","10817","10825"]},"indicator_supplement":{"属性":""}}]},{"id":"57","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2014-2016年，人纤维蛋白原批签发量由35.5万支增长至96.3万支","content_offset":["11525","11562"],"indicators":[{"indicator_name":"批签发量","indicator_value":["35.5万支增长至96.3万支","11547","11562"],"indicator_element":{"时间":["2014-2016年","11525","11535"],"产品":["人纤维蛋白原","11536","11542"]},"indicator_supplement":{"属性":""}}]},{"id":"58","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2016-2019年均复合增速约为-4.42%","content_offset":["11583","11606"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["-4.42%","11600","11606"],"indicator_element":{"时间":["2016-2019年","11583","11593"],"产品":["人纤维蛋白原","11536","11542"]},"indicator_supplement":{"属性":""}}]},{"id":"59","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2020年全年，人纤维蛋白原整体批签发139.9万支（+66.32%）","content_offset":["11607","11642"],"indicators":[{"indicator_name":"批签发量","indicator_value":["139.9万支","11626","11633"],"indicator_element":{"时间":["2020年全年","11607","11614"],"产品":["人纤维蛋白原","11615","11621"]},"indicator_supplement":{"属性":""}}]},{"id":"60","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2020年全年，人纤维蛋白原整体批签发139.9万支（+66.32%）","content_offset":["11607","11642"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+66.32%","11634","11641"],"indicator_element":{"时间":["2020年全年","11607","11614"],"产品":["人纤维蛋白原","11615","11621"]},"indicator_supplement":{"属性":""}}]},{"id":"61","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2020年Q1/Q2/Q3/Q4分别批签发26.7/36.9/19.3/57.0万支","content_offset":["11643","11685"],"indicators":[{"indicator_name":"批签发量","indicator_value":["26.7","11664","11668"],"indicator_element":{"时间":["2020年Q1","11643","11650"],"产品":["人纤维蛋白原","11615","11621"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["36.9","11669","11673"],"indicator_element":{"时间":["Q2","11651","11653"],"产品":["人纤维蛋白原","11615","11621"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["19.3","11674","11678"],"indicator_element":{"时间":["Q3","11654","11656"],"产品":["人纤维蛋白原","11615","11621"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["57.0万支","11679","11685"],"indicator_element":{"时间":["Q4","11657","11659"],"产品":["人纤维蛋白原","11615","11621"]},"indicator_supplement":{"属性":""}}]},{"id":"62","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"分别同比增长-0.97%/+139.36%/-14.29%/+196.37%","content_offset":["11686","11724"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-0.97%","11692","11698"],"indicator_element":{"时间":["2020年Q1","11643","11650"],"产品":["人纤维蛋白原","11615","11621"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["+139.36%","11699","11707"],"indicator_element":{"时间":["Q2","11651","11653"],"产品":["人纤维蛋白原","11615","11621"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-14.29%","11708","11715"],"indicator_element":{"时间":["Q3","11654","11656"],"产品":["人纤维蛋白原","11615","11621"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["+196.37%","11716","11724"],"indicator_element":{"时间":["Q4","11657","11659"],"产品":["人纤维蛋白原","11615","11621"]},"indicator_supplement":{"属性":""}}]},{"id":"63","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2014-2020年，人凝血因子VIII年均复合增速+15.55%","content_offset":["12415","12448"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["+15.55%","12441","12448"],"indicator_element":{"时间":["2014-2020年","12415","12425"],"产品":["人凝血因子VIII","12426","12435"]},"indicator_supplement":{"属性":""}}]},{"id":"64","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2020年人凝血因子VIII整体批签发198.4万支","content_offset":["12449","12475"],"indicators":[{"indicator_name":"批签发量","indicator_value":["","12449","12449"],"indicator_element":{"时间":["2020年","12449","12454"],"产品":["人凝血因子VIII","12454","12463"]},"indicator_supplement":{"属性":""}}]},{"id":"65","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"同比+14.41%","content_offset":["12476","12485"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["","12476","12476"],"indicator_element":{"时间":["2020年","12420","12425"],"产品":["人凝血因子VIII","12405","12414"]},"indicator_supplement":{"属性":""}}]},{"id":"66","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"其中Q1/Q2/Q3/Q4批签发量分别为60.2万支/43.7万支/64.8万支/29.7万支","content_offset":["12486","12533"],"indicators":[{"indicator_name":"批签发量","indicator_value":["60.2万支","12506","12512"],"indicator_element":{"时间":["Q1","12488","12490"],"产品":["人凝血因子VIII","12405","12414"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["43.7万支","12513","12519"],"indicator_element":{"时间":["Q2","12491","12493"],"产品":["人凝血因子VIII","12405","12414"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["64.8万支","12520","12526"],"indicator_element":{"时间":["Q3","12494","12496"],"产品":["人凝血因子VIII","12405","12414"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["29.7万支","12527","12533"],"indicator_element":{"时间":["Q4","12497","12499"],"产品":["人凝血因子VIII","12405","12414"]},"indicator_supplement":{"属性":""}}]},{"id":"67","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"同比增速分别为+78.89%/+34.17%/+22.36%/-45.2%","content_offset":["12534","12571"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["+78.89%","12541","12548"],"indicator_element":{"时间":["Q1/Q2/Q3/Q4","12488","12499"],"产品":["人凝血因子VIII","12454","12463"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量年复合增长率","indicator_value":["+34.17%","12549","12556"],"indicator_element":{"时间":["Q1/Q2/Q3/Q4","12488","12499"],"产品":["人凝血因子VIII","12454","12463"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量年复合增长率","indicator_value":["+22.36%","12557","12564"],"indicator_element":{"时间":["Q1/Q2/Q3/Q4","12488","12499"],"产品":["人凝血因子VIII","12454","12463"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量年复合增长率","indicator_value":["-45.2%","12565","12571"],"indicator_element":{"时间":["Q1/Q2/Q3/Q4","12488","12499"],"产品":["人凝血因子VIII","12454","12463"]},"indicator_supplement":{"属性":""}}]},{"id":"68","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2016-2019年，狂犬病人免疫球蛋白批签发量大幅增长，由2016年309.9万支增长至2019年1270.5万支","content_offset":["13068","13126"],"indicators":[{"indicator_name":"批签发量","indicator_value":["309.9万支","13103","13110"],"indicator_element":{"时间":["2016-2019年","13068","13078"],"产品":["狂犬病人免疫球蛋白","13079","13088"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["1270.5万支","13118","13126"],"indicator_element":{"时间":["2016-2019年","13068","13078"],"产品":["狂犬病人免疫球蛋白","13079","13088"]},"indicator_supplement":{"属性":""}}]},{"id":"69","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"年均复合增速达+60.05%","content_offset":["13127","13141"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["+60.05%","13134","13141"],"indicator_element":{"时间":["2016-2019年","13068","13078"],"产品":["狂犬病人免疫球蛋白","13058","13067"]},"indicator_supplement":{"属性":""}}]},{"id":"70","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2020年全年，狂犬病人免疫球蛋白批签发1169.8万支","content_offset":["13142","13170"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1169.8万支","13162","13170"],"indicator_element":{"时间":["2020年全年","13142","13149"],"产品":["狂犬病人免疫球蛋白","13150","13159"]},"indicator_supplement":{"属性":""}}]},{"id":"71","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"同比-7.92%","content_offset":["13171","13179"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-7.92%","13173","13179"],"indicator_element":{"时间":["2020年全年","13142","13149"],"产品":["狂犬病人免疫球蛋白","13079","13088"]},"indicator_supplement":{"属性":""}}]},{"id":"72","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"其中Q1/Q2/Q3/Q4批签发量分别为247.1万支/338.8万支/263.3万支/320.7万支","content_offset":["13180","13231"],"indicators":[{"indicator_name":"批签发量","indicator_value":["247.1万支","13200","13207"],"indicator_element":{"时间":["Q1","13182","13184"],"产品":["狂犬病人免疫球蛋白","13150","13159"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["338.8万支","13208","13215"],"indicator_element":{"时间":["Q2","13185","13187"],"产品":["狂犬病人免疫球蛋白","13150","13159"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["263.3万支","13216","13223"],"indicator_element":{"时间":["Q3","13188","13190"],"产品":["狂犬病人免疫球蛋白","13150","13159"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["320.7万支","13224","13231"],"indicator_element":{"时间":["Q4","13191","13193"],"产品":["狂犬病人免疫球蛋白","13150","13159"]},"indicator_supplement":{"属性":""}}]},{"id":"74","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"同比增速分别为+21.31%/+15.50%/-41.19%/-1.58%","content_offset":["13232","13269"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+21.31%","13239","13246"],"indicator_element":{"时间":["Q1","13182","13184"],"产品":["狂犬病人免疫球蛋白","13150","13159"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["+15.50%","13247","13254"],"indicator_element":{"时间":["Q2","13185","13187"],"产品":["狂犬病人免疫球蛋白","13150","13159"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-41.19%","13255","13262"],"indicator_element":{"时间":["Q3","13188","13190"],"产品":["狂犬病人免疫球蛋白","13150","13159"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-1.58%","13263","13269"],"indicator_element":{"时间":["Q4","13191","13193"],"产品":["狂犬病人免疫球蛋白","13150","13159"]},"indicator_supplement":{"属性":""}}]},{"id":"75","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2014-2019年，破伤风人免疫球蛋白批签发量整体增长迅速，由2014年209.6万支增长至2019年659.1万支","content_offset":["14296","14355"],"indicators":[{"indicator_name":"批签发量","indicator_value":["209.6万支","14333","14340"],"indicator_element":{"时间":["2014年","14328","14333"],"产品":["破伤风人免疫球蛋白","14307","14316"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["659.1万支","14348","14355"],"indicator_element":{"时间":["2019年","14301","14306"],"产品":["破伤风人免疫球蛋白","14307","14316"]},"indicator_supplement":{"属性":""}}]},{"id":"76","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"年均复合增速达+25.75%","content_offset":["14356","14370"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["+25.75%","14363","14370"],"indicator_element":{"时间":["2014-2019年","14296","14306"],"产品":["破伤风人免疫球蛋白","14307","14316"]},"indicator_supplement":{"属性":""}}]},{"id":"77","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2020年全年，破伤风人免疫球蛋白批签发618.4万支","content_offset":["14371","14398"],"indicators":[{"indicator_name":"批签发量","indicator_value":["618.4万支","14391","14398"],"indicator_element":{"时间":["2020年全年","14371","14378"],"产品":["破伤风人免疫球蛋白","14379","14388"]},"indicator_supplement":{"属性":""}}]},{"id":"78","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"同比-6.16%","content_offset":["14399","14407"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-6.16%","14401","14407"],"indicator_element":{"时间":["2020年全年","14371","14378"],"产品":["破伤风人免疫球蛋白","14307","14316"]},"indicator_supplement":{"属性":""}}]},{"id":"79","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"其中Q1/Q2/Q3/Q4批签发量分别为162.1万支/138.7万支/127.3万支/190.3万支","content_offset":["14408","14459"],"indicators":[{"indicator_name":"批签发量","indicator_value":["162.1万支","14428","14435"],"indicator_element":{"时间":["Q1","14410","14412"],"产品":["破伤风人免疫球蛋白","14379","14388"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["138.7万支","14436","14443"],"indicator_element":{"时间":["Q2","14413","14415"],"产品":["破伤风人免疫球蛋白","14379","14388"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["127.3万支","14444","14451"],"indicator_element":{"时间":["Q3","14416","14418"],"产品":["破伤风人免疫球蛋白","14379","14388"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["190.3万支","14452","14459"],"indicator_element":{"时间":["Q4","14419","14421"],"产品":["破伤风人免疫球蛋白","14379","14388"]},"indicator_supplement":{"属性":""}}]},{"id":"80","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"同比增速分别为+41.92%/-6.18%/-45.38%/+16.1%","content_offset":["14460","14496"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+41.92%","14467","14474"],"indicator_element":{"时间":["Q1","14410","14412"],"产品":["破伤风人免疫球蛋白","14379","14388"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-6.18%","14475","14481"],"indicator_element":{"时间":["Q2","14413","14415"],"产品":["破伤风人免疫球蛋白","14379","14388"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-45.38%","14482","14489"],"indicator_element":{"时间":["Q3","14416","14418"],"产品":["破伤风人免疫球蛋白","14379","14388"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["+16.1%","14490","14496"],"indicator_element":{"时间":["Q4","14419","14421"],"产品":["破伤风人免疫球蛋白","14379","14388"]},"indicator_supplement":{"属性":""}}]},{"id":"81","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2014-2019年，乙型肝炎人免疫球蛋白整体批签发量小幅下滑，由2014年289.6万支下降至2019年224.9万支","content_offset":["15464","15524"],"indicators":[{"indicator_name":"批签发量","indicator_value":["289.6万支289.6万支","-1","-1"],"indicator_element":{"时间":["2014年","15497","15502"],"产品":["乙型肝炎人免疫球蛋白","15475","15485"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["224.9万支","15517","15524"],"indicator_element":{"时间":["2019年","15469","15474"],"产品":["乙型肝炎人免疫球蛋白","15475","15485"]},"indicator_supplement":{"属性":""}}]},{"id":"82","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"年均复合增速为-4.93%","content_offset":["15525","15538"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["-4.93%","15532","15538"],"indicator_element":{"时间":["2014-2019年","15464","15474"],"产品":["乙型肝炎人免疫球蛋白","15475","15485"]},"indicator_supplement":{"属性":""}}]},{"id":"83","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2020年全年，乙型肝炎人免疫球蛋白批签发216.3万支","content_offset":["15539","15567"],"indicators":[{"indicator_name":"批签发量","indicator_value":["216.3万支","15560","15567"],"indicator_element":{"时间":["2020年全年","15539","15546"],"产品":["乙型肝炎人免疫球蛋白","15547","15557"]},"indicator_supplement":{"属性":""}}]},{"id":"84","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"同比-3.83%","content_offset":["15568","15576"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-3.83%","15570","15576"],"indicator_element":{"时间":["2020年全年","15539","15546"],"产品":["乙型肝炎人免疫球蛋白","15475","15485"]},"indicator_supplement":{"属性":""}}]},{"id":"85","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"其中Q1/Q2/Q3/Q4批签发量分别为50.1万支/27.3万支/68.3万支/70.7万支","content_offset":["15577","15624"],"indicators":[{"indicator_name":"批签发量","indicator_value":["50.1万支","15597","15603"],"indicator_element":{"时间":["Q1/Q2/Q3/Q4","15579","15590"],"产品":["乙型肝炎人免疫球蛋白","15547","15557"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["27.3万支","15604","15610"],"indicator_element":{"时间":["Q1/Q2/Q3/Q4","15579","15590"],"产品":["乙型肝炎人免疫球蛋白","15547","15557"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["68.3万支","15611","15617"],"indicator_element":{"时间":["Q1/Q2/Q3/Q4","15579","15590"],"产品":["乙型肝炎人免疫球蛋白","15547","15557"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["70.7万支","15618","15624"],"indicator_element":{"时间":["Q1/Q2/Q3/Q4","15579","15590"],"产品":["乙型肝炎人免疫球蛋白","15547","15557"]},"indicator_supplement":{"属性":""}}]},{"id":"86","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"同比增速分别为+279.02%/-71.24%/+276.03%/-28.37%","content_offset":["15625","15665"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+279.02%","15632","15640"],"indicator_element":{"时间":["Q1","15579","15581"],"产品":["乙型肝炎人免疫球蛋白","15547","15557"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-71.24%","15641","15648"],"indicator_element":{"时间":["Q2","15582","15584"],"产品":["乙型肝炎人免疫球蛋白","15547","15557"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["+276.03%","15649","15657"],"indicator_element":{"时间":["Q3","15585","15587"],"产品":["乙型肝炎人免疫球蛋白","15547","15557"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-28.37%","15658","15665"],"indicator_element":{"时间":["Q4","15588","15590"],"产品":["乙型肝炎人免疫球蛋白","15547","15557"]},"indicator_supplement":{"属性":""}}]},{"id":"87","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2020年国产白蛋白批签发2102万支（-2.82%）","content_offset":["16180","16207"],"indicators":[{"indicator_name":"批签发量","indicator_value":["2102万支","16193","16199"],"indicator_element":{"时间":["2020年","16180","16185"],"产品":["白蛋白","16187","16190"],"渠道":["国产","16185","16187"]},"indicator_supplement":{"属性":""}}]},{"id":"88","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2020年国产白蛋白批签发2102万支（-2.82%）","content_offset":["16180","16207"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-2.82%","16200","16206"],"indicator_element":{"时间":["2020年","16180","16185"],"产品":["白蛋白","16187","16190"],"渠道":["国产","16185","16187"]},"indicator_supplement":{"属性":""}}]},{"id":"89","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2020年Q1/Q2/Q3/Q4国产白蛋白批签发量分别为529万支/530万支/621万支/422万支","content_offset":["5684","5735"],"indicators":[{"indicator_name":"批签发量","indicator_value":["529万支","5712","5717"],"indicator_element":{"时间":["2020年Q1","5684","5691"],"产品":["白蛋白","5702","5705"],"渠道":["国产","5700","5702"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["530万支","5718","5723"],"indicator_element":{"时间":["Q2","5692","5694"],"产品":["白蛋白","5702","5705"],"渠道":["国产","5700","5702"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["621万支","5724","5729"],"indicator_element":{"时间":["Q3","5695","5697"],"产品":["白蛋白","5702","5705"],"渠道":["国产","5700","5702"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["422万支","5730","5735"],"indicator_element":{"时间":["Q4","5698","5700"],"产品":["白蛋白","5702","5705"],"渠道":["国产","5700","5702"]},"indicator_supplement":{"属性":""}}]},{"id":"90","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"同比增速分别为+11.0%/+3.6%/-2.7%/-21.3%","content_offset":["5736","5768"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+11.0%","5743","5749"],"indicator_element":{"时间":["2020年Q1","5684","5691"],"产品":["白蛋白","5666","5669"],"渠道":["国产","5700","5702"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["+3.6%","5750","5755"],"indicator_element":{"时间":["Q2","5692","5694"],"产品":["白蛋白","5666","5669"],"渠道":["国产","5700","5702"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-2.7%","5756","5761"],"indicator_element":{"时间":["Q3","5647","5649"],"产品":["白蛋白","5666","5669"],"渠道":["国产","5700","5702"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-21.3%","5762","5768"],"indicator_element":{"时间":["Q4","5650","5652"],"产品":["白蛋白","5666","5669"],"渠道":["国产","5700","5702"]},"indicator_supplement":{"属性":""}}]},{"id":"91","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2020年进口批签发3835万支（+18.2%）","content_offset":["16457","16481"],"indicators":[{"indicator_name":"批签发量","indicator_value":["3835万支","16467","16473"],"indicator_element":{"时间":["2020年","16457","16462"],"产品":["白蛋白","16443","16446"],"渠道":["进口","16462","16464"]},"indicator_supplement":{"属性":""}}]},{"id":"92","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2020年进口批签发3835万支（+18.2%）","content_offset":["16457","16481"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+18.2%","16474","16480"],"indicator_element":{"时间":["2020年","16457","16462"],"产品":["白蛋白","16443","16446"],"渠道":["进口","16462","16464"]},"indicator_supplement":{"属性":""}}]},{"id":"93","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"2020Q1/Q2/Q3/Q4进口白蛋白批签发量分别为1012万支/1020万支/820万支/820万支","content_offset":["-1","-1"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1012万支","26","32"],"indicator_element":{"时间":["2020年Q1","428","435"],"产品":["2白蛋白","-1","-1"],"渠道":["进口","14","16"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["1020万支","33","39"],"indicator_element":{"时间":["Q2","6","8"],"产品":["2白蛋白","-1","-1"],"渠道":["进口","14","16"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["820万支","40","45"],"indicator_element":{"时间":["Q3","9","11"],"产品":["2白蛋白","-1","-1"],"渠道":["进口","14","16"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["820万支","40","45"],"indicator_element":{"时间":["Q4","12","14"],"产品":["2白蛋白","-1","-1"],"渠道":["进口","14","16"]},"indicator_supplement":{"属性":""}}]},{"id":"94","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"同比增速分别为+148.5%/+13.5%/-13.6%/-0.6%","content_offset":["5875","5909"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+148.5%","5882","5889"],"indicator_element":{"时间":["2020年Q1","6299","6306"],"产品":["白蛋白","5784","5787"],"渠道":["进口","5782","5784"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["+13.5%","5890","5896"],"indicator_element":{"时间":["Q2","5829","5831"],"产品":["白蛋白","5784","5787"],"渠道":["进口","5782","5784"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-13.6%","5897","5903"],"indicator_element":{"时间":["Q3","5832","5834"],"产品":["白蛋白","5784","5787"],"渠道":["进口","5782","5784"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-0.6%","5904","5909"],"indicator_element":{"时间":["Q4","5835","5837"],"产品":["白蛋白","5784","5787"],"渠道":["进口","5782","5784"]},"indicator_supplement":{"属性":""}}]},{"id":"95","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"我国年采浆量约为9000吨","content_offset":["18855","18868"],"indicators":[{"indicator_name":"采浆量","indicator_value":["约为9000吨","18861","18868"],"indicator_element":{"区域":["我国","18855","18857"],"行业":["血制品","19013","19016"]},"indicator_supplement":{"属性":""}}]},{"id":"96","source_document":"2020年血制品批签发跟踪：白蛋白进入提价窗口期.pdf","content":"而测算需求浆量约1.4万吨","content_offset":["18869","18882"],"indicators":[{"indicator_name":"采浆量","indicator_value":["约1.4万吨","18876","18882"],"indicator_element":{"区域":["我国","18855","18857"],"行业":["血制品","19013","19016"]},"indicator_supplement":{"属性":""}}]}]}